Jean-Jacques Le Fur's questions to Inventiva (IVA) leadership • Q4 2021
Question
Jean-Jacques Le Fur from Bryan, Garnier & Co posed three questions: 1) The reasoning for choosing the 800mg dose of lanifibranor over the 1,200mg dose for the LEGEND trial. 2) An update on the preclinical YAP/TEAD oncology program. 3) The key drivers for the projected €100 million in spending for the upcoming year.
Answer
CMO Michael Cooreman and executive Pierre Broqua clarified that the 800mg dose was selected for LEGEND because it demonstrates maximal efficacy on the primary endpoint, HbA1c, with no significant difference compared to the 1,200mg dose on metabolic markers. Pierre Broqua also reported that for the YAP/TEAD program, lead compounds are now advancing into in-vivo models for hepatic and renal cancer. CFO Jean Volatier stated that the significant increase in cash burn is almost entirely driven by the ramp-up of the NATiV3 Phase III trial, including increased CRO and CDMO costs.